Self-assembled peptide–poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis

Developing safe and efficient non-viral delivery systems remains a major challenge for in vivo applications of gene therapy, especially in cystic fibrosis. Unlike conventional cationic polymers or lipids, the emerging poloxamine-based copolymers display promising in vivo gene delivery capabilities. However, poloxamines are invalid for in vitro applications and their in vivo transfection efficiency is still low compared with viral vectors. Here, we show that peptides developed by modular design approaches can spontaneously form compact and monodisperse nanoparticles with poloxamines and nucleic acids via self-assembly. Both messenger RNA and plasmid DNA expression mediated by peptide-poloxamine nanoparticles are greatly boosted in vitro and in the lungs of cystic fibrosis mice with negligible toxicity. Peptide–poloxamine nanoparticles containing integrating vectors enable successful in vitro and in vivo long-term restoration of cystic fibrosis transmembrane conductance regulator deficiency with a safe integration profile. Our dataset provides a new framework for designing non-viral gene delivery systems qualified for in vivo genetic modifications.A nanoparticle self-assembled by a multi-modular peptide and an amphiphilic poloxamine serves as a non-viral gene delivery agent for the long-term expression of CFTR in cell cultures and in animal models of cystic fibrosis.

[1]  Y. Kong,et al.  Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium , 2015, Nature Communications.

[2]  J. Marshall,et al.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis , 1990, Cell.

[3]  S. L. Hyatt,et al.  Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. , 2004, Human gene therapy.

[4]  S. Hart,et al.  Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. , 2011, Biomaterials.

[5]  P. Palange,et al.  Cystic fibrosis , 2016, The Lancet.

[6]  Gregg A. Duncan,et al.  Barriers to inhaled gene therapy of obstructive lung diseases: A review. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Wei Chen,et al.  Retargeting sleeping beauty transposon insertions by engineered zinc finger DNA-binding domains. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[9]  Randall J. Platt,et al.  Therapeutic genome editing: prospects and challenges , 2015, Nature Medicine.

[10]  Justin Hanes,et al.  Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. , 2011, Angewandte Chemie.

[11]  D. Escande,et al.  Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. , 2004, Nucleic acids research.

[12]  P. Hackett Integrating DNA vectors for gene therapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  S. E. Barker,et al.  Targeted Gene Delivery to Human Airway Epithelial Cells with Synthetic Vectors Incorporating Novel Targeting Peptides Selected by Phage Display , 2004, Journal of drug targeting.

[14]  Hans Clevers,et al.  A functional CFTR assay using primary cystic fibrosis intestinal organoids , 2013, Nature Medicine.

[15]  D. Meyerholz,et al.  Origins of cystic fibrosis lung disease. , 2015, The New England journal of medicine.

[16]  David K. Meyerholz,et al.  Disruption of the CFTR Gene Produces a Model of Cystic Fibrosis in Newborn Pigs , 2008, Science.

[17]  David R. Liu,et al.  Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2015 .

[18]  A. Zoso,et al.  Animal and model systems for studying cystic fibrosis. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[19]  J. Keith Joung,et al.  Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2014, Nature Biotechnology.

[20]  J. S. St. George,et al.  Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. , 2001, Human gene therapy.

[21]  Theresa A. Storm,et al.  Large-Scale Molecular Characterization of Adeno-Associated Virus Vector Integration in Mouse Liver , 2005, Journal of Virology.

[22]  B. Singh,et al.  Hybrid nonviral/viral vector systems for improved piggyBac DNA transposon in vivo delivery. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Elias Fattal,et al.  Parameters affecting organization and transfection efficiency of amphiphilic copolymers/DNA carriers. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[24]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[25]  Steve Cunningham,et al.  Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial , 2015 .

[26]  Y. C. Chai,et al.  Preclinical and clinical advances in transposon-based gene therapy , 2017, Bioscience reports.

[27]  Z. Ivics,et al.  Specifically integrating vectors for targeted gene delivery: progress and prospects , 2017 .

[28]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[29]  J. Rosenecker,et al.  Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration , 2015, PloS one.

[30]  A. Doherty,et al.  Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis , 2016, Thorax.

[31]  J. Rosenecker,et al.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice , 2011, Nature Biotechnology.

[32]  A. Concheiro,et al.  Poloxamine-based nanomaterials for drug delivery. , 2010, Frontiers in bioscience.

[33]  K. Jensen,et al.  In vitro and ex vivo strategies for intracellular delivery , 2016, Nature.

[34]  F. Stanke,et al.  Spontaneous rescue from cystic fibrosis in a mouse model , 2006, BMC Genetics.

[35]  Shu Wang,et al.  Self-assembled ternary complexes of plasmid DNA, low molecular weight polyethylenimine and targeting peptide for nonviral gene delivery into neurons. , 2007, Biomaterials.

[36]  Y. Kong,et al.  Correction of F508del CFTR in airway epithelium using nanoparticles delivering triplex-forming PNAs , 2015, Nature communications.

[37]  J. Riordan,et al.  Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. , 2005, Molecular biology of the cell.

[38]  Z. Izsvák,et al.  Gene Therapy with the Sleeping Beauty Transposon System. , 2017, Trends in genetics : TIG.

[39]  Thomas Ferkol,et al.  Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. , 2007, Human gene therapy.

[40]  A. Trapani,et al.  Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier. , 2015, Pulmonary pharmacology & therapeutics.

[41]  Samuel K. Lai,et al.  Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[42]  Hans Clevers,et al.  Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.

[43]  J. Darcourt,et al.  Evaluation of tetrafunctional block copolymers as synthetic vectors for lung gene transfer. , 2015, Biomaterials.

[44]  Gregg A. Duncan,et al.  The Mucus Barrier to Inhaled Gene Therapy. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  R. Hartmann,et al.  Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[46]  Samuel K Lai,et al.  PEGylation for enhancing nanoparticle diffusion in mucus☆ , 2017, Advanced drug delivery reviews.

[47]  J. S. Suk,et al.  Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy , 2015, Proceedings of the National Academy of Sciences.

[48]  S. Dowdy Overcoming cellular barriers for RNA therapeutics , 2017, Nature Biotechnology.

[49]  Michael P Boyle,et al.  The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. , 2009, Biomaterials.

[50]  B. Pitard,et al.  Relationships between the physicochemical properties of an amphiphilic triblock copolymers/DNA complexes and their intramuscular transfection efficiency , 2006, Nucleic acids research.

[51]  Hao Yin,et al.  Delivery technologies for genome editing , 2017, Nature Reviews Drug Discovery.

[52]  Daniel G. Anderson,et al.  In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. , 2014, Nature nanotechnology.

[53]  Ciaran M. Lee,et al.  Correction of the ΔF508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene by Zinc-Finger Nuclease Homology-Directed Repair , 2012, BioResearch open access.